Key result
Pulmonary artery denervation is presented as a novel treatment modality for pulmonary arterial hypertension, a disease characterized by sympathetic and RAAS over-activation.
Pulmonary artery denervation is highlighted as a potential novel treatment for pulmonary arterial hypertension by targeting sympathetic nervous system over-stimulation.
Answers are grounded in this paper and cite their sources.
Supports targeting sympathetic overdrive in PAH; leaves open the clinical role of pulmonary artery denervation pending controlled trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Le et al. (2019) conducted a review in Pulmonary arterial hypertension. Pulmonary artery denervation was evaluated. Pulmonary artery denervation is presented as a novel treatment modality for pulmonary arterial hypertension, a disease characterized by sympathetic and RAAS over-activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: